CN102294009A - Chinese medicinal composition for treating rheumatoid arthritis - Google Patents

Chinese medicinal composition for treating rheumatoid arthritis Download PDF

Info

Publication number
CN102294009A
CN102294009A CN2011102531425A CN201110253142A CN102294009A CN 102294009 A CN102294009 A CN 102294009A CN 2011102531425 A CN2011102531425 A CN 2011102531425A CN 201110253142 A CN201110253142 A CN 201110253142A CN 102294009 A CN102294009 A CN 102294009A
Authority
CN
China
Prior art keywords
parts
radix
medicines
root
rhizoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN2011102531425A
Other languages
Chinese (zh)
Other versions
CN102294009B (en
Inventor
宋立学
Original Assignee
宋立学
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 宋立学 filed Critical 宋立学
Priority to CN201110253142.5A priority Critical patent/CN102294009B/en
Publication of CN102294009A publication Critical patent/CN102294009A/en
Application granted granted Critical
Publication of CN102294009B publication Critical patent/CN102294009B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Abstract

The invention provides a Chinese medicinal composition for treating rheumatoid arthritis, which is compounded according to chief medicines, deputy medicines, adjuvant medicines and envoy medicines. According to the formula, the Chinese medicinal composition comprises the following components in part by weight: 18 parts of fortune's drynaria rhizome, 12 parts of malaytea scurfpea fruit, 15 parts of prepared rehmannia root, 12 parts of epimedium herb and 12 parts of antler piece or antler glue which serve as the chief medicines, 12 parts of incised notopterygium rhizome, 30 parts of east Asian tree fern rhizome, 18 parts of himalayan teasel root, 10 parts of heracleum, 20 parts of bark of eucommia, 12 parts of common yam rhizome, 12 parts of Chinese angelica, 9 parts of szechuan lovage rhizome, 12 parts of white paeony root, 6 parts of roasted ephedra, 6 parts of dried ginger, 15 parts of clematis root, 12 parts of divaricate saposhnikovia root, 12 parts of white stiff silkworm, 30 parts of raw pearl barley and 9 parts of cassia twig which serve as the deputy medicines, 6 parts of roasted naze, 10 parts of largehead atractylodes rhizome and 50 parts of astragalus which serve as the adjuvant medicines, and 9 parts of yellowmouth dutchmanspipe root, 9 parts of liquoric root and 12 parts of twotooth achyranthes root which serve as the envoy medicines. The rheumatoid arthritis is diagnosed and treated according to a diagnostic standard which is amended by American college of rheumatology in 1987; symptoms of 30 percent of patients are completely improved, symptoms of 33 percent of patients are obviously improved, symptoms of 30 percent of patients are improved, and symptoms of 7 percent of patients are not improved, namely the total symptom improvement rate is approximately 93 percent; and the Chinese medicinal composition has a definite curative effect and a good treatment effect.

Description

A kind of Chinese medicine composition for the treatment of rheumatoid arthritis
Technical field
The invention belongs to the field of Chinese medicines, relate to a kind of Chinese medicine composition for the treatment of rheumatoid arthritis
Background technology
Rheumatoid arthritis (rheumatoid arthritis) be a kind of be the chronic systemic autoimmune disease of feature with the articular synovitis.Synovitis is outbreak repeatedly lastingly, the destruction that can cause intraarticular cartilage and bone, and joint function disturbance, in addition maimed, pathological changes is involved each organ of whole body, so primary disease is called rheumatoid disease again.
Rheumatoid arthritis is sent out well in little joints such as hands, wrist, foots, and outbreak is symmetrical distribution repeatedly.Joint red and swollen heat pain and dysfunction are arranged in early days, and late period, stiff deformity in various degree can appear in the joint, and with bone and skeletal muscle atrophy, very easily disabled.From the angle of pathological change, rheumatoid arthritis is a kind of synovium of joint (can feed through to articular cartilage, osseous tissue, articular ligament and flesh key later on) that mainly involves, and is the popularity diseases associated with inflammation of connective tissues such as serous coat, the heart, lung and eye secondly.The general performance of rheumatoid arthritis also has heating, fatigue and weak, pericarditis, subcutaneous nodule, pleuritis, arteritis, peripheral neuropathy etc. except that arthropathy.Generalized rheumatoid arthritis also comprises the popularity pathological changes of whole body except that the inflammatory disorders of joint part.
The rheumatoid arthritis journey is long. the disability rate height. mostly be sudden onset. and invisible stronger.Modern medicine is many advocates drug combination based on Western medicine more, and lesions of liver and kidney is bigger, be difficult to adhere to long-term treatment mostly, and Drug resistance occurs frequently.(list of references: rheumatoid arthritis, author: Yang Huiqin chief editor, publishing house: Chinese Medicine science and technology publishing house publication time: 2010-1-1)
Summary of the invention
For the better advantage and the effect of performance Chinese medicine rheumatoid arthritis, the invention provides a kind of Chinese medicine composition for the treatment of rheumatoid arthritis.
A kind of Chinese medicine composition for the treatment of rheumatoid arthritis provided by the invention carries out prescription according to monarch, and the prescription of its composition and weight ratio is: monarch drug is: Rhizoma Drynariae 18, Fructus Psoraleae 12, Radix Rehmanniae Preparata 15, Herba Epimedii 12, Cornu Cervi tablet or Colla cornus cervi 12; Ministerial drug is: Rhizoma Et Radix Notopterygii 12, Rhizoma Cibotii 30, Radix Dipsaci 18, Radix Angelicae Pubescentis 10, the Cortex Eucommiae 20, Rhizoma Dioscoreae 12, Radix Angelicae Sinensis 12, Rhizoma Chuanxiong 9, the Radix Paeoniae Alba 12, Herba Ephedrae (processed) 6, Rhizoma Zingiberis 6, Radix Clematidis 15, Radix Saposhnikoviae 12, Bombyx Batryticatus 12, raw pearl barley 30; Ramulus Cinnamomi 9; Adjuvant drug is: process Squama Manis 6, the Rhizoma Atractylodis Macrocephalae 10, the Radix Astragali 50; Messenger drug is: Radix Stephaniae Tetrandrae 9, Radix Glycyrrhizae 9, Radix Achyranthis Bidentatae 12.
According to the theory of Chinese medicine and pharmacy, as follows for the dispensing information of a kind of Chinese medicine composition for the treatment of rheumatoid arthritis provided by the invention: Rhizoma Drynariae is mended bone blood stasis dispelling bone strengthening; The Fructus Psoraleae kidney-replenishing warms up the public region; Marrow is filled out in the Radix Rehmanniae Preparata the kidney invigorating, and spermatogenesis nourishes blood, and Colla cornus cervi the kidney invigorating arteries and veins is supported essence and blood; The Herba Epimedii invigorating the liver and kidney, beneficial vital essence is monarch drug altogether; The notopterygium wind dispelling dehumidifying, with the strong waist knee joint of Rhizoma Cibotii, wind-damp dispelling, kidney tonifying is strengthened waist knee joint, sharp pitching; The Radix Dipsaci invigorating the liver and kidney, bone and muscle strengthening; Waist, bone and muscle strengthening are strengthened in Cortex Eucommiae the kidney invigorating; Radix Angelicae Pubescentis is searched the Shao Yin Fufeng; Ramulus Cinnamomi and battalion defend the meridian dredging, aid yang qi; Rhizoma Dioscoreae. Radix Angelicae Sinensis. Rhizoma Chuanxiong. the Radix Paeoniae Alba hemopoietic of enriching blood, hemapodium is then through ruton; The Herba Ephedrae dispersing wind and cold is joined the warm flesh natural fibre line of meat of Radix Rehmanniae Preparata energy, changes carbuncle of yin nature; The Rhizoma Zingiberis warming the meridian is supporing yang; Radix Clematidis leads to 12 warps, dispelling wind evil; Fang-feng powder wind and cold wins damp; Bombyx Batryticatus is dispeled the wind, and removes stiff knot; Raw pearl barley dampness removing Shujin; Be ministerial drug altogether
Process Squama Manis and search wind and pick network, the priming sick institute that goes directly; Rhizoma Atractylodis Macrocephalae spleen reinforcing stomach reinforcing; Radix Astragali invigorating QI to consolidate the body surface resistance; Be adjuvant drug altogether.
The Radix Stephaniae Tetrandrae wind-expelling pain-stopping, the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, Radix Achyranthis Bidentatae stasis of blood kidney tonifying alive, priming is gone into kidney; Be messenger drug altogether.
A kind of method for making for the treatment of the Chinese medicine composition of rheumatoid arthritis provided by the invention: (1) by formula proportion measure Bombyx Batryticatus 12g, process Squama Manis 6g, Cornu Cervi tablet or Colla cornus cervi 12g 30g altogether, pulverize, standby; (2) surplus medicine gross weight is 360g, is to add water at 360: 750 by the ratio of surplus medicine gross weight g and the volume mL of water, and cold water soaked 30 minutes, was boiled into herb liquid 400mL after boiling, and is standby.
Usage and dosage: (1) divides two equal portions 30g powder medicine, every part of 15g earlier; (2) also be divided into two equal portions and warm being boiled into 400 milliliters of herb liquids; (3) use warm herb liquid then, the powder medicine is taken after mixing it with water.Be grown up one day twice, sooner or later respectively once.30 days is a course of treatment.
Emr treatment and observation of curative effect: shared this side accepts 1792 people for medical treatment from February, 1998 to 2010 year JIUYUE, wherein women 1523 people, and male 269 people the oldest 72 years old, minimum 17 years old, 29 years old mean age, are the out-patient.Administration time is the longest nine months, and is the shortest 33 days.All meet the diagnosis of rheumatoid arthritis standard.
Diagnostic criteria: the diagnostic criteria according to Americanism damp disease association revision in 1987 is as follows:
(1) morning deadlock.
(2) pain or tenderness is arranged during at least one joint motion.
(3) at least one arthroncus (soft tissue plumpness or hydrops but not hyperosteogeny, by the doctor is seen).
(4) another arthroncus at least (being seen that by the doctor two joint involvement institute interludes should be no more than 3 months).
(5) the same joint when invading proximal phalangeal joints, metacarpophalangeal joints or toe joint (if do not need complete symmetry) of body both sides is invaded in symmetry arthroncus (being seen by the doctor) simultaneously, and involving of distal interphalangeal joint can not be satisfied this standard.
(6) bone protrusion or juxtra-articular are stretched the subcutaneous nodule (being seen by the doctor) of side.
(7) the X-ray film finding of standard (outside the deossification hypertrophy, must have the osteoporosis of the juxtra-articular of getting involved to exist).
(8) the rheumatoid factor positive.
(9) mucin solidifies not good in the synovial membrane liquid.
(10) have three or more in the following synovial membrane pathological change: tangible fine hair hypertrophy; Top layer synovial cell proliferation and be paliform; Significantly chronic inflammation cell (being mainly lymphocyte and plasma cell) soaks into and forms the trend of lymph node; The fibrin deposition of densification in a top layer or the matter; Focal necrosis.
(11) display centre district necrocytosis kitchen range is answered by the Histological change in the subcutaneous nodule, round outgrowth macrophage of paliform and outermost chronic inflammatory cell infiltration.
Typical case's rheumatoid arthritis: its diagnostic criteria needs 7 in the above-mentioned project.In the item of (1)-(5), the joint symptom must continue for 6 weeks at least.
Affirm rheumatoid arthritis: its diagnosis needs 5 in the above-mentioned project.In the item of (1)-(5), the joint symptom must continue for 6 weeks at least.
A kind of Chinese medicine composition observation of curative effect and functional assessment for the treatment of rheumatoid arthritis provided by the invention: adopting (1) domestic functional assessment commonly used is to be used for patient's functional status to assess comparatively reliable and responsive method for comparatively simple health evaluating questionnaire (HAQ) and (2) arthritis influence index (AIMS).The particular content of AIMS sees Table 1-1-2.
(1) domestic functional assessment commonly used is that the particular content of comparatively simple health evaluating questionnaire (HAQ) is as follows:
The inquiry patient carry out in a week in the past following when movable situation and keep the score: 0-does not have influence, some difficulty of 1-, 2-is very difficult, 3-can not carry out.
1) wears the clothes;
2) comb one's hair;
3) not having support from chair stands;
4) go to bed, get up;
5) drinking-water of cheering;
6) cut the dish;
7) uncork plug;
8) level walking out of doors;
9) last 5 grades of stair;
10) have a bath, dry;
11) washroom up and down;
12) bend over to pick up thing on the ground;
13) stretch out one's hand and take thing on the wall;
14) switch faucet;
15) get on or off the bus;
16) go window-shopping;
17) do housework, as sweep;
18) walking is one kilometer;
19) participate in the activity of being liked;
20) sleep in evening.
(2) to influence index (AIMS) be to be used for the comparatively reliable and responsive method of patient's functional status assessment to arthritis.Swelling pain disappears or idol has pain.The particular content of AIMS sees Table 1-1-2.
The 1-1-2 joint influences index
Beneficial effect: according to the diagnostic criteria of above-mentioned diagnostic criteria according to Americanism damp disease association revision in 1987, from in February, 1998 to 2010 year JIUYUE, for meeting above-mentioned diagnosis of rheumatoid arthritis standard, be total to diagnosis and treatment 1792 people, wherein women 1523 people, male 269 people, the oldest 72 years old, minimum 17 years old, 29 years old mean age, be the out-patient.Administration time is the longest nine months, and is the shortest 33 days.According to (1) domestic functional assessment commonly used is the method that comparatively simple health evaluating questionnaire (HAQ) and (2) arthritis influence index (AIMS), and a kind of Chinese medicine composition efficacy result for the treatment of rheumatoid arthritis provided by the invention is as follows: treat 1792 people altogether.Wherein, symptom is improved 537 people fully, accounts for 30%, and symptom is obviously improved 597 people, accounts for 33%, doing well,improving 532 people, and 30%, symptom does not have improvement 126, accounts for 7%, symptom improvement rate always about 93%.The result shows, a kind of Chinese medicine composition determined curative effect and therapeutic effect for the treatment of rheumatoid arthritis provided by the invention is good.
The specific embodiment
Embodiment 1 a kind of Chinese medicine composition for the treatment of rheumatoid arthritis provided by the invention carries out prescription according to monarch, and the prescription of its composition and weight ratio is: monarch drug is: Rhizoma Drynariae 18, Fructus Psoraleae 12, Radix Rehmanniae Preparata 15, Herba Epimedii 12, Cornu Cervi tablet or Colla cornus cervi 12; Ministerial drug is: Rhizoma Et Radix Notopterygii 12, Rhizoma Cibotii 30, Radix Dipsaci 18, Radix Angelicae Pubescentis 10, the Cortex Eucommiae 20, Rhizoma Dioscoreae 12, Radix Angelicae Sinensis 12, Rhizoma Chuanxiong 9, the Radix Paeoniae Alba 12, Herba Ephedrae (processed) 6, Rhizoma Zingiberis 6, Radix Clematidis 15, Radix Saposhnikoviae 12, Bombyx Batryticatus 12, raw pearl barley 30; Ramulus Cinnamomi 9; Adjuvant drug is: process Squama Manis 6, the Rhizoma Atractylodis Macrocephalae 10, the Radix Astragali 50; Messenger drug is: Radix Stephaniae Tetrandrae 9, Radix Glycyrrhizae 9, Radix Achyranthis Bidentatae 12.
According to the theory of Chinese medicine and pharmacy, as follows for the dispensing information of a kind of Chinese medicine composition for the treatment of rheumatoid arthritis provided by the invention: Rhizoma Drynariae is mended bone blood stasis dispelling bone strengthening; The Fructus Psoraleae kidney-replenishing warms up the public region; Marrow is filled out in the Radix Rehmanniae Preparata the kidney invigorating, and spermatogenesis nourishes blood, and Colla cornus cervi the kidney invigorating arteries and veins is supported essence and blood; The Herba Epimedii invigorating the liver and kidney, beneficial vital essence is monarch drug altogether; The notopterygium wind dispelling dehumidifying, with the strong waist knee joint of Rhizoma Cibotii, wind-damp dispelling, kidney tonifying is strengthened waist knee joint, sharp pitching; The Radix Dipsaci invigorating the liver and kidney, bone and muscle strengthening; Waist, bone and muscle strengthening are strengthened in Cortex Eucommiae the kidney invigorating; Radix Angelicae Pubescentis is searched the Shao Yin Fufeng; Ramulus Cinnamomi and battalion defend the meridian dredging, aid yang qi; Rhizoma Dioscoreae. Radix Angelicae Sinensis. Rhizoma Chuanxiong. the Radix Paeoniae Alba hemopoietic of enriching blood, hemapodium is then through ruton; The Herba Ephedrae dispersing wind and cold is joined the warm flesh natural fibre line of meat of Radix Rehmanniae Preparata energy, changes carbuncle of yin nature; The Rhizoma Zingiberis warming the meridian is supporing yang; Radix Clematidis leads to 12 warps, dispelling wind evil; Fang-feng powder wind and cold wins damp; Bombyx Batryticatus is dispeled the wind, and removes stiff knot; Raw pearl barley dampness removing Shujin; Be ministerial drug altogether
Process Squama Manis and search wind and pick network, the priming sick institute that goes directly; Rhizoma Atractylodis Macrocephalae spleen reinforcing stomach reinforcing; Radix Astragali invigorating QI to consolidate the body surface resistance; Be adjuvant drug altogether.
The Radix Stephaniae Tetrandrae wind-expelling pain-stopping, the Radix Glycyrrhizae coordinating the actions of various ingredients in a prescription, Radix Achyranthis Bidentatae stasis of blood kidney tonifying alive, priming is gone into kidney; Be messenger drug altogether.
A kind of method for making for the treatment of the Chinese medicine composition of rheumatoid arthritis provided by the invention: (1) by formula proportion measure Bombyx Batryticatus 12g, process Squama Manis 6g, Cornu Cervi tablet or Colla cornus cervi 12g 30g altogether, pulverize, standby; (2) surplus medicine gross weight is 360g, is to add water at 360: 750 by the ratio of surplus medicine gross weight g and the volume mL of water, and cold water soaked 30 minutes, was boiled into herb liquid 400mL after boiling, and is standby.
Usage and dosage: (1) divides two equal portions 30g powder medicine, every part of 15g earlier; (2) also be divided into two equal portions and warm being boiled into 400 milliliters of herb liquids; (3) use warm herb liquid then, the powder medicine is taken after mixing it with water.Be grown up one day twice, sooner or later respectively once.30 days is a course of treatment.

Claims (1)

1. a Chinese medicine composition for the treatment of rheumatoid arthritis is characterized in that, carries out prescription according to monarch, and the prescription of its composition and weight ratio is as follows: (1) monarch drug is: Rhizoma Drynariae 18, Fructus Psoraleae 12, Radix Rehmanniae Preparata 15, Herba Epimedii 12, Cornu Cervi tablet or Colla cornus cervi 12; (2) ministerial drug is: Rhizoma Et Radix Notopterygii 12, Rhizoma Cibotii 30, Radix Dipsaci 18, Radix Angelicae Pubescentis 10, the Cortex Eucommiae 20, Rhizoma Dioscoreae 12, Radix Angelicae Sinensis 12, Rhizoma Chuanxiong 9, the Radix Paeoniae Alba 12, Herba Ephedrae (processed) 6, Rhizoma Zingiberis 6, Radix Clematidis 15, Radix Saposhnikoviae 12, Bombyx Batryticatus 12, raw pearl barley 30; Ramulus Cinnamomi 9; (3) adjuvant drug is: process Squama Manis 6, the Rhizoma Atractylodis Macrocephalae 10, the Radix Astragali 50; (4) messenger drug is: Radix Stephaniae Tetrandrae 9, Radix Glycyrrhizae 9, Radix Achyranthis Bidentatae 12.
CN201110253142.5A 2011-08-31 2011-08-31 Chinese medicinal composition for treating rheumatoid arthritis Active CN102294009B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201110253142.5A CN102294009B (en) 2011-08-31 2011-08-31 Chinese medicinal composition for treating rheumatoid arthritis

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201110253142.5A CN102294009B (en) 2011-08-31 2011-08-31 Chinese medicinal composition for treating rheumatoid arthritis

Publications (2)

Publication Number Publication Date
CN102294009A true CN102294009A (en) 2011-12-28
CN102294009B CN102294009B (en) 2014-10-15

Family

ID=45354842

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201110253142.5A Active CN102294009B (en) 2011-08-31 2011-08-31 Chinese medicinal composition for treating rheumatoid arthritis

Country Status (1)

Country Link
CN (1) CN102294009B (en)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755622A (en) * 2012-07-24 2012-10-31 李淑芳 Medicine for treating rheumatoid arthritis
CN103599486A (en) * 2013-11-22 2014-02-26 山东省立医院 Traditional Chinese medicine composition for treating rheumatoid arthritis by being taken orally
CN103816450A (en) * 2014-03-12 2014-05-28 张利民 Traditional Chinese medicine for treating rheumatoid arthritis
CN104042979A (en) * 2014-07-04 2014-09-17 华梅 Traditional Chinese medicine wine for treating rheumatoid arthritis and preparation method thereof
CN104491795A (en) * 2014-12-16 2015-04-08 广东聚智诚科技有限公司 Traditional Chinese medicine composition for treating rheumatoid arthritis
CN104940556A (en) * 2014-03-31 2015-09-30 洪从贵 Externally applied traditional Chinese medicine liquid for treating arthritis
CN105169307A (en) * 2015-08-25 2015-12-23 孙太辉 Drug for treating rheumatoid arthritis and preparation method thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
刘征堂等: "中医药治疗类风湿性关节炎的临床研究进展 ", 《四川中医》 *
刘征堂等: "中医药治疗类风湿性关节炎的临床研究进展", 《四川中医》, vol. 19, no. 04, 15 April 2001 (2001-04-15), pages 24 - 26 *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102755622A (en) * 2012-07-24 2012-10-31 李淑芳 Medicine for treating rheumatoid arthritis
CN102755622B (en) * 2012-07-24 2013-09-11 李淑芳 Medicine for treating rheumatoid arthritis
CN103599486A (en) * 2013-11-22 2014-02-26 山东省立医院 Traditional Chinese medicine composition for treating rheumatoid arthritis by being taken orally
CN103816450A (en) * 2014-03-12 2014-05-28 张利民 Traditional Chinese medicine for treating rheumatoid arthritis
CN103816450B (en) * 2014-03-12 2016-04-06 郑于静 A kind of Chinese medicine for the treatment of rheumatoid arthritis
CN104940556A (en) * 2014-03-31 2015-09-30 洪从贵 Externally applied traditional Chinese medicine liquid for treating arthritis
CN104042979A (en) * 2014-07-04 2014-09-17 华梅 Traditional Chinese medicine wine for treating rheumatoid arthritis and preparation method thereof
CN104491795A (en) * 2014-12-16 2015-04-08 广东聚智诚科技有限公司 Traditional Chinese medicine composition for treating rheumatoid arthritis
CN105169307A (en) * 2015-08-25 2015-12-23 孙太辉 Drug for treating rheumatoid arthritis and preparation method thereof

Also Published As

Publication number Publication date
CN102294009B (en) 2014-10-15

Similar Documents

Publication Publication Date Title
CN102294009B (en) Chinese medicinal composition for treating rheumatoid arthritis
CN104587090A (en) Medicine for treating rheumatoid arthritis
CN103191383B (en) Traditional Chinese medicine composition for treating rheumatoid arthritis
CN100368001C (en) Medicine composition for treating rheumatic arthritis and rheumatoid arthritis, and its prepn. method
CN103505659A (en) Chinese proprietary medicine for treating rheumatoid arthritis
CN102274481A (en) Chinese medicinal preparation for treating rheumatoid arthritis
CN1966066A (en) Ointment for unblocking collaterals and relieving pain and preparation process threreof
CN101040949B (en) Medicine compound for creating rheumatism and rheumatoid arthritis and the preparing method and application
CN103735752A (en) Traditional Chinese medicine for treating ankylosing spondylitis
CN102512645B (en) Traditional Chinese medicine composition for treating lumbago due to cold dampness
CN103735647A (en) Medicated wine for treating chronic infectious arthritis
CN103989968B (en) A kind of oral medication stenosis Chinese medicine composition
CN100381161C (en) Medicine ointment for treating swelling and pain in waist and knees
CN102423344A (en) Traditional Chinese medicine for curing calcaneodynia
CN102512543B (en) Chinese medicinal composition for treating rheumatoid arthritis
CN104771489A (en) Traditional Chinese medicine composition for treating rheumatoid arthritis
CN102600251B (en) Rheumatism-rehabilitating traditional Chinese formulation
CN108404045A (en) A kind of ointment and preparation method thereof
CN104666881B (en) A kind of Chinese medicine composition for treating talagia
CN104958743A (en) Traditional Chinese medicine composition for treating rheumatoid arthritis (RA)
CN101264225B (en) Orally-administered decoction for treating ulcer in tongue base
CN105560737A (en) Traditional Chinese medicine composition for treating rheumatoid arthritis
CN102631594B (en) Medicament for treating rheumatoid arthritis
CN104958481A (en) Traditional Chinese medicine for treating rheumatoid arthritis (RA) due to yin deficiency and collateral heat
CN102430066B (en) Sciatic nerve liquid

Legal Events

Date Code Title Description
PB01 Publication
C06 Publication
SE01 Entry into force of request for substantive examination
C10 Entry into substantive examination
GR01 Patent grant
C14 Grant of patent or utility model